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1  Introduction
The combination of one-pot multi-step operations and 
organocatalysis is an elegant, economically attractive 
method, which has gained considerable attention in modern 
synthetic chemistry [1-10]. Such synthesis usually relies on 
the use of organocatalysts prepared in advance [5-10].
Recently, we disclosed a new one-pot synthetic approach 
employing organocatalysts, prepared in situ via one-pot 
transformations and subsequently used for enantioselective 
synthesis of 1,2-amino alcohol derived chiral drugs [11]. 
According to our new approach, not only the target chiral 
compound, but also the organocatalyst required for its 
enantioselective formation can be synthesized in a one-pot 
procedure without intermediate isolation or purification 
steps, leading to the reduction of costs, saving of materials, 
time, effort and contributing further to the sustainability of 
the one-pot process. 
To extend this concept further and to demonstrate its 
generality, we present here the application of our approach 
to the synthesis of convolutamydine A, which involves a 
two-step one-pot sequence, namely in situ organocatalyst 
formation (through reduction of amino acids L-Leu 1a or 
L-Val 1b to catalytically active amino alcohols) and addition 
of acetone to 4,6-dibromoisatin. (R)-Convolutamydine A is a 
member of the oxindole subfamily, which exhibits a potent 
inhibitory activity on the differentiation of HL-60 human 
leukaemia cells [12]. 
The most convenient synthetic pathway towards 
enantiopure convolutamydine  A is the direct aldol 
reaction of acetone with 4,6-dibromoisatin. Few chiral 
organocatalysts have been developed for the preparation of 
convolutamydine A using this aldol addition in moderate to 
high enantioselectivities (Scheme 1) [13-16].
Nonetheless, the reported synthetic methodologies 
towards (R)-convolutamydine  A employ external 
organocatalysts (Scheme 1), prepared in advance which 
require isolation and purification. To meet the basic needs 
of the pharmaceutical chemistry, synthetic methods towards 
synthesis of chiral drugs must be simple, straightforward 
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2   S. Wei et al.
and environmentally friendly [17]. Thus, finding a new facile 
and direct access to (R)-convolutamydine  A under mild 
reaction conditions and without intermediary workup and 
purification steps is highly attractive. 
2  Results and Discussion
Following our previous work on organocatalytic aldol 
reactions[18,19] and applying our expertise in the research 
fields of the organocatalytic construction of quaternary 
carbon centers[20-22] we decided to study the direct aldol 
reaction of acetone with 4,6-dibromoisatin. 
Since amino alcohols 2a and 2b have already been 
reported by one of us as active external catalysts for the 
aldol addition of acetone to 4,6-dibromoisatin (entries 
1 and 2, Table 1) [15],  we were interested in exploring 
whether selected amino alcohols 2c-2f would perform as 
well as or even better than catalysts 2a and 2b  in the same 
aldol addition. Reactions were run at room temperature 
in CH2Cl2 under conditions employing 20 mol% of amino 
alcohols and water (100 mol%) as an additive (Table 1). The 
use of (S)-proline derived catalyst 2c gave the S-configured 
product in high yield (93%), but with only 4% ee (entry 3). 
Interestingly, without water additive the carene 
derived catalyst 2d provides the (S)-convolutamydine A 
with 44% yield and 51% ee (entry 4), while addition 
of 100 mol% of water additive leads to the opposite 
enantiomer (R)-convolutamydine A with 23% yield and 
13% ee (entry 5). It seems that the enantioselectivity 
of the monoterpene based catalyst 2d can be reversed 
in the presence of water additive. Further studies are 
required to obtain more insight into the observed 
unusual switch in the enantioselectivity. Notably, in 
2011 Wennemers and co-workers reported another 
intriguing example of reversal of enantioselectivity 
by changing the nature of the reaction medium in the 
tripeptide catalyzed aldol reaction of cyclohexanone 
and 4-nitrobenzaldehyde [23]. 
Next, application of two diastereoisomeric amino 
alcohols 2e and 2f gave the same R-configured product with 
similar results (entries 6 and 7, Table 1) regarding yields 
(90% und 98%, respectively) and enantioselectivities 
(77% ee and 78% ee, correspondingly). These 
observations demonstrate that the dominating influence 
on the absolute configuration of the resulting product 
convolutamydine  A resides in the stereogenic carbon 
center of the chiral catalyst adjacent to the amine group. 
These results also suggest the involvement of enamine 
activation mechanism.
Thus, under the same reaction conditions 
catalysts 2c-2f, as alternatives of 2a and 2b, promoted a 
less-stereoselective aldol transformation to afford the 
S- or R-configured convolutamydine A (entries 3-7 vs. 
entries 1 and 2, Table 1). Therefore, chiral amino alcohols 
2a and 2b were selected as catalysts for further studies. 
Commercially available and cheap amino acids L-Leu 1a 
and L-Val 1b were used as starting materials for the in 
situ formation of selected chiral organocatalytic amino 
alcohols L-leucinol (2a) and L-valinol (2b). 
For in situ generation of the corresponding vicinal 
amino alcohols (Table 2), we decided to apply previously 
optimized borane reduction of the amino acids employing 
BH3-THF (1.5 equiv.) in THF under reflux conditions [11]. No 
racemisation of the corresponding amino alcohols 2a and 
2b/2b’ was observed under the selected reaction conditions. 
Starting with L-Leu 1a and carrying out the proposed 
one-pot reaction without any additive, we isolated the 
product, convolutamydine A in 30% yield in racemic 
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Scheme 1: Known chiral organocatalysts for the aldol reaction of acetone with 4,6-dibromoisatin.
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form (entry 1, Table 2). Further optimisation of the two-
step one-pot sequence revealed the necessity of presence 
of water as an additive in the aldol reaction step. 
Increasing the amount of water led to improved yield and 
enantioselectivity of (S)-convolutamydine A (Table 2). We 
found that the addition of 5.0 equiv. of water resulted in 
84% yield and 80% enantioselectivity (entry 4, Table 2) 
after a relatively short reaction time.                                                                                                      
Interestingly, larger amounts of water (e.g., 208.0 
equiv.) resulted in decreased yield without loss of 
selectivity (65%, 85% ee, Table 2, entries 5-7).
Notably, a plausible transition state model was 
suggested for this aldol reaction catalyzed by external 
leucinol [15], which fits well with the experimental data, 
but does not include an explicit molecule of water. 
Therefore, it can be reasoned, that the presence of water 
in our one-pot reaction leads to an increase in the active 
catalyst 2a concentration, facilitating the enamine 
mechanism proposed previously [15]. Indeed, water might 
favour the release of the catalytically active free 1,2-amino 
Table 1: Synthesis of convolutamydine A using external chiral amino alcohols as catalysts.
Br
Br
N
H
O
Br
Br
N
H
O
O
O
+
HO
O
cat. (20 mol%)
H2O (additive)
*CH2Cl2, r.t., time
 
Entry Catalyst Water additive(mol%)
Time, h a Yield (%)b ee (%)c
1d
H2N OH
2a
100 36 98 95 (S)
2d H2N OH
2b
100 36 84 95 (S)
3
NH
O
N
H OH
Ph
2c
100 48 93 4 (S)
4
H2N OH
2d
0 36 44 51 (S)e
5
H2N OH
2d
100 48 23 13 (R)f
6
H2N
OHPh
Ph
2e
100 144 90 77 (R)
7
H2N
OHPh
Ph
2f
100 48 98 78 (R)
 
a Reaction time required for complete conversion.  b Yields of isolated products. c Determined by chiral phase HPLC analysis and compared with 
authentic racemic material. d Yields and ee-values have been previously reported [15].  e [α]D = +25.2 (c 0.29, MeOH).  f [α]D = -6.36 (c 0.015, MeOH).
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of the catalyst and the keto group of dibromoisatin in the 
transition state. This agrees with the decrease of selectivity 
observed in protic solvents like methanol [15].
Based on the pre-optimisation with L-leucine shown 
in Table 2, we next studied the reproducibility of the two-
step one-pot synthesis using two different amino acids, 
namely L-leucine 1a and D-valine 1b’. In general, L-amino 
acids preferentially afford the (S)-enantiomer (entries 1, 2 
and 4, Table 3), while D-amino acids (e.g. (R)-1b’, entries 3 
and 5) gave the desired (R)-configured convolutamydine A.
Consequently, we optimized the synthesis of the 
natural product convolutamydine A in a one-pot reaction 
over two steps. We obtained the product in reproducible 
high yields and good ee-values (80-95% yields and 73-80% 
ees, entries 1-5, Table 3). Leucine 1a gave better ee-values 
than valine 1b. Further improvement of the ee-values of 
convolutamydine A with respect to the value determined 
directly from the crude reaction mixture should be 
possible by means of crystallization [15].
3  Conclusions 
In summary, the synthesis of an anti-leukaemia agent 
convolutamydine A via a two-step one-pot transformation 
involving in situ chiral organocatalyst formation from 
commercially available inexpensive starting materials 
(α-amino acids) has been investigated. The advantages 
of such one-pot reactions are the reduction of work-up 
and purification steps, resulting in lower costs, material 
and labor input, which makes the multi-step sequential 
synthesis even more efficient, atom economical and 
environmentally friendly. 
4  Experimental Section 
4.1  General 
Solvents were purified by standard procedures and 
distilled prior to use. Reagents purchased from commercial 
sources were used without further purification. TLC 
chromatography was performed on pre-coated aluminium 
silica gel ALUGRAM® SIL G/UV254 plates (Macherey-Nagel 
GmbH&Co.). Flash chromatography was performed using 
silica gel Merck 60 (particle size 0.040-0.063 mm). 1H 
NMR and 13C NMR spectra were recorded on Bruker Avance 
400 NMR spectrometer using the solvent as internal 
standard. The enantiomeric excess of products was 
determined by chiral HPLC analysis (using chiral column: 
Daicel Chiralpak IA) in comparison with authentic 
alcohol 2a from the oxazaborolidine intermediate, which 
could be formed after the reduction step. 
The decrease of reaction selectivity and yield at very 
high levels of water may be due to interference of water 
molecules with the hydrogen bond between the OH-group 
Table 2: Pre-optimisation of reaction conditions for one-pot synthe-
sis of convolutamydine A.
Br
Br
N
H
O
Br
Br
N
H
O
O
O
+
HO
O
H2N CO2H H2N OHBH3.THF (1.5 equiv.)
Additive 
(equiv.) 
CH2Cl2, r.t.
time
THF, reflux, 3 h
2a1a
Entry Additive 
(equiv.)
Time, h Yield (%)a ee (%)b  (S)
1 - 36 30 rac
2 H2O (1.0) 24 70 75
3 H2O (3.0) 36 60 79
4 H2O (5.0) 18 84 80
5 H2O (7.0) 18 79 85
6 H2O (9.0) 18 75 80
7 H2O (208.0) 18 65 85
 
aYields of isolated products. bDetermined by chiral phase HPLC ana-
lysis and compared with authentic racemic material.
Table 3: One-pot organocatalyst / convolutamydine A sequential 
synthesis.
Br
Br
N
H
O
Br
Br
N
H
O
O
O
+
HO
O
H2N OHBH3.THF (1.5 equiv.)
H2O
(equiv.)
CH2Cl2, r.t.
time
THF, reflux
2a and 2b or 2b'
H2N CO2H
R
(S)-Leu 1a and 
(S)-Val 1b or 
(R)-Val 1b'
*
convolutamydine A
R
Entry Amino acid Time, h Yield (%)a ee (%)b
1 (S)-Leu 1ac 18 84 80 (S)
2 (S)-Leu 1ac 18 80 75 (S)
3 (R)-Val 1b’d 18 95 70 (R) 
4 (S)-Val 1bd 18 82 77 (S)
5 (R)-Val 1b’d 16 92 73 (R)
 
aYields of isolated products. bDetermined by chiral phase HPLC 
analysis and compared with authentic racemic material. cReduction 
of 1a under reflux for 3 h. dd Reduction of 1b and 1b’ under reflux for 
17 h.
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racemic material. HPLC measurements were performed 
using Agilent Technologies 1200 Series equipment. A 
PerkinElmer 341 polarimeter was used for optical rotation 
measurements.
4.2   One-pot procedure for the synthesis of 
(R)-convolutamydine A:
To a stirred solution of D-Valine (32 mg, 0.27 mmol) in dry 
THF (0.41 mL) at 0°C, was added BH3·THF (0.41 mL, 1.0 M 
in THF) via syringe. The reaction mixture was then stirred 
for 17 h under reflux. The conversion was followed by TLC. 
The reaction mixture was cooled to room temperature 
and CH2Cl2 (6.57 mL) and water (5 equiv., 0.086 mL) were 
added slowly, After 1 minute, 4,6-dibromoisatin (1 equiv., 
0.96 mmol, 290.73 mg) and acetone (30 equiv., 28.2 mmol, 
2.11 mL) were then added. The reaction mixture was stirred 
at room temperature for additional 16 h, and was then 
washed with water and dried over Na2SO4. The organic 
solvents were removed under reduced pressure and the 
residue was purified by flash chromatography on SiO2 
(ethyl acetate / petrolether 1:1) to give (R)-convolutamydine 
A as a white solid (317 mg, 92% yield, 73% ee).
The enantiomeric excess was determined by chiral 
HPLC analysis (Daicel Chiralpak IA column, λ = 210 nm, 
mobile phase n-hexane/iPrOH 85:15, flow 0.95 mL/min). 
[α]25D +43.9 (c 0.33, MeOH) [lit. [15] +48.9 (c 0.33, MeOH)]; 
1H NMR (300 MHz, DMSO-d6): δ = 2.03 (s, 3H), 3.12 (d, J = 
16.8 Hz, 1H ), 3.76 (d, J = 17.7 Hz, 1H), 6.22 (br s, 1H, OH), 
6.94 (d, J = 1.2 Hz, 1H), 7.28 (d, J = 1.2 Hz, 1H), 10.64 (s, 1H) 
ppm; 13C NMR (75 MHz, DMSO-d6): δ = 205.3, 177.3, 146.4, 
128.7, 126.7, 122.4, 119.6, 111.8, 73.7, 48.3, 30.0 ppm; IR(neat): ν 
= 3313, 3226, 1703, 1605, 1578, 1432, 1358, 1317, 1166, 1076, 
845, 677 cm-1. MS (MALDI) spectrum showed molecular 
ions [M+Na]+ at m/z 384, 386 and 388 respectively [M+K]+ 
at m/z 400, 402 and 404 in the ratio 1:2:1.
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